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Abstract
Background: Subsidised access to high-cost medicines in Australia is restricted under national
programs (the Pharmaceutical Benefits Scheme, PBS, and the Repatriation Pharmaceutical Benefits
Scheme, RPBS) with a view to achieving cost-effective use. The aim of this study was to examine
the use and associated government cost of biological agents for treating rheumatoid arthritis over
the first two years of subsidy, and to compare these data to the predicted outcomes.
Methods: National prescription and expenditure data for the biologicals, etanercept, infliximab,
adalimumab, and anakinra were collected and analysed for the period August 2003 to July 2005.
Dispensing data on biologicals sorted by the metropolitan, rural and remote zones and by
prescriber major specialty were also examined.
Results:  A total of 27,970 prescriptions for biologicals was reimbursed. The government
expenditure was A$53.1 million, representing only 19% of that expected. Almost all prescriptions
were reimbursed by the PBS (98%, A$52 million) and the remainder by the RPBS. Approximately
62% of the prescriptions were for concessional patients (A$32.9 million). There was considerable
variability in the use of biologicals across Australian states and territories, usage roughly correlating
with the per capita adjusted number of rheumatologists. The total number of prescriptions
continued to increase over the study period. Etanercept was the most highly prescribed agent (74%
by number of prescriptions), although its use was beginning to plateau. Use of adalimumab
increased steadily. Use of infliximab and anakinra was considerably lower. The resultant health
outcomes for individual patients are unknown. Prescribers from capital cities and other
metropolitan centres provided a majority of prescriptions of biologicals (89%).
Conclusion: The overall uptake of biologicals for treating rheumatoid arthritis over the first two
years of PBS subsidy was considerably lower than expected. Long-term safety concerns and the
expanded clinical uses of these drugs emphasise the need for evaluation. It is essential that there is
comprehensive, ongoing analysis of utilisation data, associated expenditure and, importantly,
patient outcomes in order to enhance accountability, efficiency and equity of policies that allocate
substantial resources to subsidising national access to high-cost medicines.
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Background
Expenditure on pharmaceuticals has increased rapidly in
many countries in the last decade [1]. Access to medicines
is increasingly problematic for healthcare systems and
individuals as healthcare resources are finite and innova-
tive medicines expensive. Critical but conflicting issues
under discussion are: which medicines should be subsi-
dised; who should have access to such drugs; what restric-
tions should apply to access; and what is a reasonable
distribution of that cost between government and the
individual patient? Arrangements for access to medicines
need to be managed well so that they are acceptable to
consumers, clinicians, the government and the industry.
The Pharmaceutical Benefits Scheme (PBS) is Australia's
drug reimbursement system that has supported national
access to a wide range of medicines for the community
since the 1950s. This system has attracted considerable
attention worldwide as Australian drug prices are mark-
edly lower than those in comparable countries, although
prices paid for innovative medicines are similar [2]. The
PBS is an uncapped scheme. The fiscal sustainability of the
PBS has been under intense scrutiny by federal health and
financial public policy makers in recent years because gov-
ernment outlays on subsidised prescription medicines
have continued to increase at a rate greater than other
areas of health care [3]. In part, this disproportionate
expenditure reflects the cost of the new biotechnology-
derived drugs. The challenge posed by increasing expend-
iture on pharmaceuticals and demand for innovative
expensive medicines will be even more prominent in the
future. Controlling government expenditure on the PBS
while maintaining social equity and access to 'essential
medicines' is at the centre of an ongoing public debate.
Careful examination of the recent developments in target-
ing access to high-cost medicines in Australia is instructive
in informing the debate concerning the principles and
processes that might underpin appropriate and ethical
access to expensive medicines under the PBS or similar
reimbursement systems.
The Pharmaceutical Benefits Advisory Committee
(PBAC), an independent committee consisting of clinical
experts, health economists, and a consumer representa-
tive, recommends to the Federal Minister for Health
which medicines should be 'listed' on the PBS. The PBAC
decisions are based on an evaluation of comparative effi-
cacy and safety as well as cost-effectiveness of medicines
(including quality-adjusted life-years) [4]. Australia was
the first country to introduce a mandatory requirement
for economic analysis to select pharmaceuticals for a pub-
licly funded formulary in 1993 [5]. Use of economic eval-
uation to inform decisions about reimbursing drugs has
been adopted globally, including countries such as the
United Kingdom, Canada, and New Zealand [6-10]. The
PBS decisions have a direct budgetary impact and PBAC is
responsible for recommending drug prices [11]. The PBS
has established complex controls to balance the benefits,
risks, and costs associated with high-cost medicines by tar-
geting access to subsets of patients. PBS restrictions are
based on data (primarily from randomised controlled
clinical trials), economic evaluation (an assessment of
'value for money' taken from a long-term perspective),
and more recently and innovatively, a collaboration
between the stakeholders (the PBAC, the respective phar-
maceutical companies, and representative medical spe-
cialists) [12,13]. To gain subsidised access, patients must
meet specific eligibility criteria for both starting (severe
disease inadequately controlled by existing cheaper treat-
ments) and continuing therapy (substantial clinical
improvement). Prescribing rights are limited to specialist
physicians. These prior-approval requirements have been
applied to control access to a number of high-cost medi-
cines under the PBS. The concept of "high-cost medicines"
has not yet been clearly defined internationally. In Aus-
tralia, a broad definition of a high-cost medicine is one
whose acquisition cost is greater than A$10,000 per
patient per treatment course [14]. A representative exam-
ple is seen with the biological response modifiers for the
treatment of rheumatoid arthritis (RA) namely the
tumour necrosis factor-alpha inhibitors (TNFIs), etaner-
cept, infliximab, and adalimumab, and an interleukin-1
receptor antagonist, anakinra (about A$20,000 per
patient per year). Subsidised access to other high-cost
medicines, such as imatinib for the treatment of patients
with chronic myeloid leukaemia (about A$45,000 per
patient per year), is similarly restricted under the PBS.
Self-funding by most patients is not a realistic option for
these high-cost medicines.
The issue of subsidised access to medicines for the treat-
ment of RA and other autoimmune diseases came into
focus with the introduction of these biologicals. These
drugs markedly reduce disease activity and slow erosion
of joints in the majority of patients with RA [15] but they
are substantially more expensive than conventional dis-
ease-modifying anti-rheumatic drugs (DMARDs). A risk-
mitigation arrangement between the government and the
respective sponsors established an agreed annual ceiling
for government outlays [12]. An 'interchangeability rule'
was later introduced (December 2004) that allowed
patients with RA to trial an alternate biological without
the need to re-qualify against the initial eligibility criteria
[16]. Details of the controlled access scheme for these
medicines under the PBS are provided in Table 1.
Accurate prediction of pharmaceutical expenditure is crit-
ical if the PBS is to be sustained and limited resources allo-
cated appropriately. As part of major submissions to the
PBAC, sponsoring pharmaceutical companies are
required to estimate the uptake of the medicine and theAustralia and New Zealand Health Policy 2007, 4:2 http://www.anzhealthpolicy.com/content/4/1/2
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financial implications for at least the first 2 years [13].
These estimates are based on the prevalence of the disease
(chronic conditions) or the annual incidence (acute con-
ditions) as well as the likely market share of the new med-
icine [17]. Submissions to the PBAC for drug subsidy
containing these estimates are bound by the Australian
National Health Act (1953) and the data are treated as
'commercial-in-confidence', therefore only limited infor-
mation is made available to the public [11].
Approximately 1% of the Australian population has RA
(~200,000 Australians) [18], and it was estimated that
approximately 4,000 of these patients (i.e. approximately
2% of RA patients) would meet the proposed PBS criteria
for etanercept treatment in the first year of subsidy [19].
However, this estimate is substantially below others. For
example, it was estimated that about 5–6% of patients
with RA would qualify for a TNFI based on the inclusion
criteria for the Anti-Tumour necrosis factor Trial in Rheu-
matoid Arthritis with Concomitant Therapy (ATTRACT)
or using criteria established by the British Society of Rheu-
matology [20,21]. The PBS expenditure for biologicals in
the treatment of RA was forecast to be up to A$140 mil-
lion per annum ("cap") at the time that subsidy of etaner-
cept and infliximab was approved (2003). The basis for
these projections was not publicly available. It is also
unclear from documents available in the public domain
whether there have been any alterations to the original
forecast expenditure resulting from the subsequent PBS
subsidy of adalimumab and anakinra in 2004. Utilisation
of biologicals under the Repatriation Pharmaceutical Ben-
efits Scheme (RPBS) was not included explicitly in the
projections. The RPBS provides pharmaceutical benefits
to veterans and eligible dependants that in general con-
form to the same requirements as for the PBS.
There is limited data on comparison of estimated and
actual drug utilisation in Australia, and no study of utili-
sation of biologicals under the RPBS has yet been pub-
lished. The aim of this study was to examine the use and
government cost of biological agents for treating RA in
Australia, under the PBS and RPBS, over the first two years
of government subsidy (August 2003 to July 2005). Exam-
ination of these data is important to assess the implica-
tions of controlled access schemes for medicines. Findings
will be helpful in guiding policy and practice on manag-
ing access to high-cost medicines under drug reimburse-
ment systems such as the PBS.
Methods
This study was a retrospective analysis of data on the
national utilisation and expenditure for etanercept, inflix-
imab, adalimumab, and anakinra under the PBS and
RPBS for the period August 2003 to July 2005.
Medicare Australia (formerly the Health Insurance Com-
mission), a government statutory authority that adminis-
ters the PBS and other health programs nation-wide,
maintains an electronic database of claims for subsidised
medicines. Statistical data on reimbursement of prescrip-
Table 1: Access scheme for biological agents for the treatment of RA under the PBS
Main features Prior-approval requirements
Criteria for initiating treatment • Severe active disease:
a) elevated levels of anti-inflammatory markers (ESR > 25 mm/hour or CRP > 15 mg/L)
b) swollen and tender joints – a total of > 20 joints, or > 4 major joints (elbow, wrist, knee, ankle, shoulder, hip)
• A record of rheumatoid factor positive status (this requirement is removed as of June 2005)
• Failure to achieve adequate response to a step-up sequence of treatment with conventional DMARDs:
a) monotherapy with methotrexate (20 mg per week)
b) a combination of methotrexate (> 7.5 mg per week) and 2 other DMARDs for at least 3 months
c) leflunomide, leflunomide with methotrexate, or cyclosporin for at least 3 months
• Evidence of intolerance or contraindication to DMARDs
• Patients required to sign a 'patient acknowledgement form'
• Treatment is approved for 16 weeks only (treatment of 22 weeks is approved for infliximab)
A patient agreement process • A patient acknowledgement form to be signed by patients with their physicians to acknowledge that PBS-
subsidised treatment will only continue if the predetermined response criteria are achieved at 12 weeks
Criteria for continuing treatment • Clinical outcomes are evaluated according to predetermined quantifiable criteria at 12 weeks:
a) Reduction in levels of anti-inflammatory markers, ESR < 25 mg/hour, or CRP < 15 mg/L, or 20% from baseline 
levels
b) Reduction in the total number of joint count by 50%
'Interchangeability' (introduced December 2004) • Patients approved to commence PBS-subsidised biological treatment are allowed to switch to an alternate 
biological agent at any time (an agent that the patient has responded adequately or has not trialed previously)
Restricted prescribing rights • Prescription only by specialist rheumatologists initially. Prescribing rights were extended to clinical 
immunologists with expertise in the management of rheumatoid arthritis as of February 2004
'Risk-mitigation' arrangement  • Annual PBS expenditure for the TNF inhibitors group was predicted to be up to A$140 million
• Expenditure above this figure to be covered by the sponsoring pharmaceutical companies (details not clear from 
public documents)
Abbreviations:
ESR = erythrocyte sedimentation rate
CRP = C-reactive protein
DMARDs = disease-modifying anti-rheumatic drugsAustralia and New Zealand Health Policy 2007, 4:2 http://www.anzhealthpolicy.com/content/4/1/2
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tions and expenditure were obtained from this adminis-
trative database [22]. Relevant PBS item numbers were
[16]:
￿ Etanercept (25 mg × 8 vials/prescription): 8637N (ini-
tial treatment), 8638P (continuing treatment)
￿ Infliximab (100 mg, quantity supplied on the basis of
the weight of the patient, at a dose of 3 mg/kg for a single
infusion): 6397Q
￿ Adalimumab (40 mg × 2 injections): 8737W (initial
treatment), 8741C (continuing treatment)
￿ Anakinra (100 mg × 28 injections): 8773R (initial treat-
ment), 8774T (continuing treatment)
Methods used to interpret data from Medicare Australia
have been described elsewhere [23]. In brief, the data
comprised the number of 'services' (number of prescrip-
tions) reimbursed by Medicare Australia and the govern-
ment expenditure on these prescriptions. Patients paying
privately, or funded by private health insurance, are not
captured by the claims data. Patients must hold a valid
Medicare card in order to obtain PBS-subsidised medi-
cines and make a co-payment of A$28.60 per prescription
(A$4.60 for concessional patients; 2005 rate). Medicare
Australia reimburses pharmacies the difference between
the co-payment made by the patient and the cost of each
prescription pack of the medicine. The maximum contri-
bution for biologicals for the treatment of RA by Medicare
Australia was A$1888/prescription (four-week supply for
biologicals, except infliximab which is repeated every 6–8
weeks). Data available through Medicare Australia's web-
site are updated monthly in aggregates and can be sepa-
rated by States and Territories, and by patient categories
e.g. general, concessional (including senior and pensioner
concessions), and veterans. Although usage in public hos-
pitals is not captured (separately managed by state gov-
ernments), treatment of RA with these agents is largely
undertaken in ambulatory private practice in Australia;
except infliximab which is supplied through public and
private hospitals under the Highly Specialised Drugs Pro-
gram [24].
In order to examine any association between access to
rheumatologists and the uptake of biologicals, prescrip-
tion data were adjusted for State population numbers
obtained from the census data from the Australian Bureau
of Statistics [25]. The number of rheumatologists in each
state was obtained from the Australian Rheumatology
Association (as of November 2005). Information on the
proportion of full-time versus part-time rheumatologists,
and whether they worked primarily in private practice or
in the public system is not documented by the Associa-
tion.
Dispensing data were also obtained from the Drug Utili-
sation Sub-Committee (DUSC) of the PBAC to examine
the geographical dispensing trends. The DUSC database
contains information on all subsidised prescriptions proc-
essed by Medicare Australia under the PBS and RPBS. The
DUSC database also contains estimates of the number of
non-subsidised (private and below co-payment) prescrip-
tions from an ongoing survey in which a sample of com-
munity pharmacies provides records of all dispensed
prescriptions – costs of these non-subsidised prescriptions
are not available [26]. Aggregated prescription data on
biologicals sorted by the Rural, Remote and Metropolitan
Area (RRMA) classification system [27] and by prescriber
major specialty were examined.
In using these databases to quantify drug usage, the
assumptions are that dispensing is a good proxy for 1)
prescribing (i.e. most patients prescribed a biological
actually have it dispensed), and 2) consumption (i.e.
adherence with these agents is likely to be high). These are
reasonable assumptions for a chronic disease like RA, and
because of the costs of these medicines, and complex
process that prescribers and patients have to experience in
order to gain access.
Results
Prescriptions of biologicals under the PBS and RPBS
There was a total of 27,970 prescriptions reimbursed by
Medicare Australia between August 2003 and July 2005
for the biologicals used to treat RA (etanercept, 20,742;
infliximab, 851; adalimumab, 6,257; anakinra, 120). The
expenditure on biologicals increased steadily over the
study period; a total government expenditure of A$53.1
million – 98% by the PBS (A$52 million) and the remain-
der (A$1.1 million) by the RPBS. The estimated patient
contribution was A$267,000 over the study period (0.5%
of a total cost of A$53.4 million). Under the PBS, approx-
imately 62% of the prescriptions (17,330 prescriptions)
went to concessional patients at a cost of A$34 million,
and 36% to general patients at a cost of A$19.1 million.
Reimbursed prescriptions for biologicals doubled in the
second year accounting for 71% of total prescriptions over
the two years. The government expenditure rose propor-
tionally but was well below the "cap" of A$140 million
per year (19%). There was only a marginal increase in the
number of prescriptions for 'initial treatment' in the sec-
ond year. The proportion of prescriptions for 'continuing
treatment' increased from 50% to 72% of the total pre-
scriptions in year 2 (Figure 1). Infliximab was not
included in these estimates because prescriptions for this
biological were not stratified into 'initiating' and 'contin-Australia and New Zealand Health Policy 2007, 4:2 http://www.anzhealthpolicy.com/content/4/1/2
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uing' categories. The maximum number of prescriptions
processed in a month occurred in July 2005 – a total of
1,984 prescriptions for the biologic group (Figure 2) at a
cost A$3.75 million (Figure 3). Assuming that each pre-
scription was supplied to an individual patient, by crude
estimation approximately 2,000 patients had commenced
biological therapy for RA within the study period based
on the aggregated data. This represents about half of the
estimated 4,000 adult patients with RA predicted to be eli-
gible for etanercept in the first year. However, it was not
possible to determine the proportion of patients that were
approved to continue or who were switched between bio-
logicals.
The total number of prescriptions for etanercept under the
PBS from August 2003 to July 2005 was 20,398 (A$38.4
million). A further 344 prescriptions (A$647,500) were
reimbursed under the RPBS. Initiation of etanercept ther-
apy declined after December 2003. The use of infliximab
was considerably lower than etanercept, although inflixi-
mab was not PBS-subsidised until November 2003: 826
prescriptions were provided under the PBS (A$2.1 mil-
lion) and only 25 prescriptions (A$59,000) under the
RPBS. Adalimumab was available under the PBS from
May 2004. Up to July 2005, adalimumab had accounted
for 6,063 prescriptions (A$11.4 million) under the PBS
and 194 prescriptions (A$365,800) under the RPBS. Since
inclusion on the PBS in December 2004, anakinra had
accounted for 115 prescriptions (A$164,000) under the
PBS and 5 prescriptions (A$7,100) under the RPBS (Table
2).
Prescriptions of biologicals by Australian states and 
territories
Uptake of biologicals by State/Territory was greatest in
New South Wales (7,559 prescriptions). The relative per
capita uptake demonstrated the same pattern as seen in
the first year after listing of etanercept [23]. The Australian
Capital Territory, Tasmania and South Australia had the
highest relative per capita use of biologicals (32.7, 30.3
and 23.7 prescriptions per 10,000 population, respec-
tively). Initiations and continuations of biological thera-
pies were also highest in these states. The Northern
Territory had the lowest per capita use (Table 2). There was
an 8-fold range of ratios between the jurisdictions. After
adjusting for state population, uptake of infliximab was
the highest in Western Australia. South Australia and the
Australian Capital Territory had the highest per capita ratio
of rheumatologists, whereas Queensland had the lowest.
Prescription rates per rheumatologist were highest in Tas-
mania and the Australian Capital Territory.
Prescriptions of biologicals by rural, remote and 
metropolitan areas
Based on the DUSC dispensing data on etanercept, inflix-
imab, and adalimumab (data was supplied for Aug 2003–
Jun 2005; anakinra dispensing data were unavailable
from DUSC at the time of this study), a majority of pre-
scriptions (89.6%) were provided by prescribers in the
metropolitan areas (capital cities and other metropolitan
centres; Table 3). Regional population numbers were not
available for population-adjusted analysis. Review by the
prescriber major specialty indicated that only a small pro-
portion of prescriptions (5.7%) was provided by immu-
nologists.
Discussion
The utilisation and expenditure on biologicals for treating
RA under the PBS over the first two years was substantially
below that forecast (19% by expenditure). Uptake of
etanercept was considerably lower than projected (14%
by expenditure) in the first year [23] and the uptake rate
did not increase significantly in the second year (Figure 1).
Therefore, concerns about inappropriate or over-use of
biologicals appear to be unfounded. From this perspec-
tive, the PBS restrictions have been effective in controlling
access and containing government expenditure. By July
2005, approximately 1% of the RA patient population in
Australia had commenced biological therapy. This is sub-
stantially lower than that reported in other countries, for
example, 14.9% of patients with RA were treated with bio-
logicals in southern Sweden in 2003 [28], and about 20%
of patients with RA receive anti-TNF therapy in the United
States [29]. It needs to be acknowledged that the number
of patients and hence the expenditure on biologicals are
likely to vary with the eligibility criteria for the treatment
[30]. The low use of biologicals in Australia may reflect, in
part, the administrative burden imposed by the PBS
restrictions, which may have discouraged some applica-
tions. Administrative tasks may have also contributed to
the lower than expected registration of patients on the vol-
untary national biologicals registers established to track
patient outcomes [31]. Another possible explanation is
that there has been cautious selection of patients by rheu-
matologists because of concerns about drug safety. It is
also possible that a smaller population of RA patients
than predicted achieved the eligibility criteria for initiat-
ing biological therapy as a result of the PBS-mandated
treatment algorithm (including the use of combination
DMARD therapy). The non-biologicals regimen may have
clinically accommodated a greater proportion of patients
than expected such that criteria indicating substantial dis-
ease activity necessary for access to biologicals were no
longer met. The true value of this algorithm  needs to be
reviewed because evidence supports a conclusion that bio-
logicals  are more efficacious than DMARDs in arresting
joint damage  [32]. Withdrawal from biological therapyAustralia and New Zealand Health Policy 2007, 4:2 http://www.anzhealthpolicy.com/content/4/1/2
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may also explain lower prescribing and expenditure than
expected. It has been reported that up to 40% of patients
do not or only partially respond to biologicals [33].
Finally, it is also likely that the forecasts were inaccurate;
data assembled by pharmaceutical companies including
the economic analyses have been reported to be error
prone [34]. Both under- and over-estimates of usage com-
pared with actual usage of other drugs have been reported
in two-thirds of submissions for subsidy of medicines
made to the PBAC [35]. Summaries on submissions for
drug subsidy, including the estimation of expected usage
through the PBS and the cost to government, and the out-
comes of PBAC decisions are now published [36].
Etanercept had the highest usage over the study period.
This finding was expected because etanercept was the first
agent available under the PBS (August 2003). Further,
patients who were intolerant to methotrexate could only
be treated with etanercept. Adalimumab was more
recently approved as monotherapy in April 2005. The
gradual plateau in the utilisation of etanercept (Figure 2)
possibly reflects the introduction of adalimumab under
the PBS. The steady increase in initiations of adalimumab
treatment may reflect the fortnightly administration
schedule as compared with etanercept that is adminis-
tered twice per week. The considerably lower use of inflix-
imab is possibly due to several reasons: it must be used in
combination with methotrexate, it is used less frequently
(administered every 6–8 weeks), its usage in public hospi-
tals is not captured, and it is administered as an intrave-
nous infusion which may be much less preferred by
prescribers and patients. There has been no contrast in
efficacy outcomes between TNFIs demonstrated to date in
RA. The minimal use of anakinra can be explained by its
recent listing on the PBS (December 2004) and data that
suggest it is less efficacious than TNFIs [15]. The rate of
uptake of anakinra over the next few years is  not easily
predicted because patients who fail to respond to two
TNFIs are allowed to trial anakinra (under the 'inter-
changeability rule').
An important goal of the PBS is to provide equitable
access to medicines for the community. However, those in
equal need may not have equal opportunities to access
rheumatological services. Prescribing of these drugs under
the PBS is restricted to rheumatologists and clinical
immunologists with expertise in the management of RA.
There is a limited number of specialists and reasonable
access to a rheumatologist varies considerably between
states and territories in Australia. Not surprisingly the use
Monthly number of prescriptions for biologics under the PBS and RPBS, by initiation and continuation of therapy, August 2003– July 2005 Figure 1
Monthly number of prescriptions for biologics under the PBS and RPBS, by initiation and continuation of therapy, August 2003–
July 2005. Note: Biologics included: etanercept, adalimumab, and anakinra.Australia and New Zealand Health Policy 2007, 4:2 http://www.anzhealthpolicy.com/content/4/1/2
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of biologicals roughly correlated with the per capita ratio
of rheumatologists. Patients in remote or rural areas are
thus disadvantaged by this criterion. Prescription data by
rural, remote and metropolitan areas also indicated geo-
graphical heterogeneity in access to health care. Other fac-
tors potentially influencing the use of specialist care
include patient's income, indirect costs (e.g. travel costs,
foregone wages), access to information, knowledge, and
cultural beliefs [37]. Geographical variation in access to
biologicals has also been identified in the United King-
dom ('post code prescribing') [38].
The PBS expenditure on biologicals increased steadily
over the study period (Figure 3). Essentially the cost of
Monthly number of prescriptions for biologics under the PBS and RPBS, by drug, August 2003–July 2005 Figure 2
Monthly number of prescriptions for biologics under the PBS and RPBS, by drug, August 2003–July 2005.
Table 3: Prescriptions of biologicals by Rural, Remote, and Metropolitan Area (RRMA) classification system, based on DUSC data (Aug 
2003–Jun 2005)
RRMA Etanercept Infliximab Adalimumab Biologicals Total % of Total
Capital cities 18669 802 6396 25867 80.25
Other metropolitan 
centresa
2124 52 826 3002 9.31
Large rural centresb 1517 138 611 2266 7.03
Small rural centresc 635 5 165 805 2.50
Other rural areasd 4 401 7 6 1 0 . 2
Remote arease 2 201 3 3 5 0 . 1 1
Other remote areasf 4105 0 . 0 2
Unknown 164 1 28 193 0.6
a Other metropolitan centres: population > 100 000 [27]
b Large rural centres: population 25 000 to 99 999
c Small rural centres: population 10 000 to 24 999
d Other rural areas: population < 10 000
e Remote areas: population > 5000
f Other remote areas: <5000Australia and New Zealand Health Policy 2007, 4:2 http://www.anzhealthpolicy.com/content/4/1/2
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biologicals is covered by the government (99.5%) with a
minimal proportion contributed by patients through co-
payments. The majority of expenditure on prescriptions of
biologicals was directed towards concessional patients.
This is not surprising as the PBS restrictions select for
those patients with severe RA who are likely to suffer from
functional disability; loss of work capacity in RA patients
has been well recognised [39]. Monthly PBS expenditure
on anti-rheumatic drugs overall (including both DMARDs
and the biologicals) has doubled since the biologicals
became available; although it should be acknowledged
that not all usage of medicines classified as DMARDs is for
RA. The relatively high cost of biologicals and the increas-
ing expenditure on medicines needs to be examined
together with other costs such as cost of monitoring and
treating adverse reactions as well as the cost of managing
RA [40] (direct costs such as other health services, indirect
costs such as work disability, and intangible costs such as
pain, fatigue, and psychological distress). The potential
that these treatments may obviate the need for surgery
associated with joint destruction and progressive func-
tional disability characteristic of inappropriately control-
led RA (cost savings) needs also to be taken into
consideration [41]. The disease is associated with consid-
erable socio-economic impact on individual patients and
their families as well as on society as a whole. An esti-
mated A$246 million spent on health services including
19% on pharmaceuticals (prescribed and over-the-coun-
ter medications) in the year 2000–01 was attributable to
RA [18]. These data are concordant with a previous report
that 8–24% of the direct cost of treating RA could be
attributed to the cost of drugs [42]. The use of biologicals
may influence the use of other services. For example, a
small study in the United Kingdom reported a 55% reduc-
tion of in-patient services use while the use of out-patient
services doubled [43], a factor which also needs to be
examined. Further, the resources needed to administer the
PBS criteria are expensive because of the complexity of the
process [44]. Formal review of these costs and outcomes is
important to an understanding of the value of such con-
trolled access schemes for medicines.
There are several limitations of this analysis. The present
study emphasises an urgent need for access to comprehen-
Monthly expenditure on anti-rheumatic drugs under the PBS and RPBS, August 2003–July 2005 Figure 3
Monthly expenditure on anti-rheumatic drugs under the PBS and RPBS, August 2003–July 2005. Note: Expenditure on 
DMARDs was obtained from the Drug Utilization Sub-Committee database. DMARDs included: methotrexate, azathioprine, 
cyclophosphamide, cyclosporin, hydroxychloroquine, penicillamine, sulfasalazine, gold preparations (sodium aurothiomalate 
and auranofin), and leflunomide.Australia and New Zealand Health Policy 2007, 4:2 http://www.anzhealthpolicy.com/content/4/1/2
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sive data that would enable a more detailed examination
of the use of medicines in Australia. The data discussed
here were derived from the Medicare Australia national
administrative database, which is available through its
website [22]. De-identified, individual data on patient
demographics and usage of medicines can be purchased
from Medicare Australia, but is not readily accessible.
Data on health outcomes are also unavailable, despite
abundant information on clinical status being collected
for approval of access to biologicals [45]. Further, data on
the use of medicines, adverse drug reactions, and use of
medical services are not linked or easily available for link-
age in Australia. Utilisation of medicines and medical
services in public hospitals, managed by state govern-
ments, are also not incorporated in the national dataset.
Australia lags behind other countries in this area e.g. the
General Practice Research Database in the United King-
dom [46], and national registries established for anti-
rheumatic treatments in several countries [31,47]. These
databases hold more comprehensive datasets that can
potentially identify and address important issues, includ-
ing utilisation of medicines, and access to and quality of
health care. Developments and successes with state-based
data linkage of Commonwealth and state data such as that
established in Western Australia [48] have been encourag-
ing and will enable individual-level studies of medicine
use and associated health outcomes. Other Australian
States, including New South Wales, Queensland and
South Australia are currently establishing mechanisms for
linkage between State and Commonwealth health data
[49].
A recent report of an increased risk of serious infections, a
dose-dependent increased risk of malignancies in patients
with RA treated with biological therapies [50], as well as
the expanded clinical uses of these drugs (such as in the
treatment of psoriatic arthritis and ankylosing spondyli-
tis) also emphasise the need for ongoing surveillance.
Evaluation based on comprehensive data would enable
clearer conclusions to be reached about the clinical and
economic effects of the PBS controlled access scheme for
biologicals, specifically, the initial access criteria, the 'con-
tinuation rule', and the 'interchangeability rule'. This feed-
back is essential for decision makers to refine the criteria
and for prescribers to manage patients appropriately and
cost-effectively.
Conclusion
Utilisation of high-cost, anti-rheumatic biologicals in
Australia over the first two years of PBS subsidy has been
conservative, well below the forecast. Whether this low
uptake represents appropriate or inappropriate prescrib-
ing of biologicals in Australia cannot be determined on
the basis of the limited available information. Recent
increased transparency on how projections of utilisation
and expenditure on medicines are determined is to be
applauded. Ongoing review of PBS restrictions as new
data become available together with post-subsidy exami-
nation of drug utilisation, associated costs, and resultant
health outcomes, is important. Enhanced communication
between all parties will increase confidence in the drug
subsidy program and its decisions, and hence its sustaina-
bility as a public system. These enhancements will ensure
Table 2: Prescriptions of biologicals for rheumatoid arthritis under the PBS and RPBS by Australian States and Territories based on 
aggregate data, Aug 2003–Jul 2005
NSW VIC QLD SA WA TAS ACT NT TOTAL
Number of prescriptions
Etanercept 7 559 3 685 2 205 3 064 2 142 1 085 939 63 20 742
Infliximaba 190 182 146 51 280 2 0 0 851
Adalimumab 1 842 1 496 1 096 503 820 369 116 15 6 257
Anakinra 52 17 25 8 17 0 1 0 120
Biologicals Total 9 643 5 380 3 472 3 626 3 259 1 456 1 056 78 27 970
Biologicals Prescriptions per 10,000 populationb 14.4 10.9 9.0 23.7 6.6 30.3 32.7 3.9
Number of rheumatologistsc 86 69 32 29 24 5 5 2
Rheumatologists per 10,000 population 0.128 0.139 0.083 0.189 0.122 0.104 0.155 0.100
Biologicals Prescriptions per rheumatologist 112.1 78.0 108.5 125.0 135.8 291.2 211.2 39
Note:
a Number of prescriptions of infliximab: usage in public hospital is not included in the statistical report by Medicare Australia.
b Source: Australian Bureau of Statistics, Australian Population – States and Territories, December quarter, 2003.
c Number of rheumatologists registered as members of the Australian Rheumatology Association
Australian states and territories: NSW = New South Wales, VIC = Victoria, QLD = Queensland, SA = South Australia, WA = Western Australia, 
TAS = Tasmania, ACT = Australian Capital Territory, NT = Northern TerritoryAustralia and New Zealand Health Policy 2007, 4:2 http://www.anzhealthpolicy.com/content/4/1/2
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that there is affordable, equitable, and efficient provision
of needed medicines to the individual patient with result-
ant improved health outcomes being delivered by a
national public reimbursement system.
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